Circulation, Vol 86, 56-63, Copyright © 1992 by American Heart Association
DA Brezinski, RW Nesto and CN Serhan
BACKGROUND. Percutaneous transluminal coronary angioplasty (PTCA) is a
widely used and important method of reperfusing coronary arteries. However,
it is also associated with serious complications such as acute reocclusion
and accelerated restenosis. The factors as well as the mechanisms involved
in PTCA-associated complications remain to be fully elucidated. Because
peptidoleukotrienes and lipoxins are potent vasoactive compounds, the
formation of which is not inhibited by aspirin (ASA) treatment in vitro, it
is possible that these eicosanoids are involved in PTCA-associated untoward
events. To test this, we determined the intracoronary levels of
peptidoleukotrienes and lipoxin A4 (LXA4) as well as thromboxane (TX) and
5S,12S- dihydroxyeicosatetraenoic acid (5S,12S-DiHETE; a product of double
dioxygenation) after plaque rupture and evaluated the impact of ASA
therapy. METHODS AND RESULTS. PTCA was performed on 12 patients with
coronary artery disease, six undergoing ASA therapy and six without ASA
therapy, for at least 2 weeks before PTCA. By means of a technique that
permitted sampling of intracoronary blood at the plaque site in situ,
samples were taken immediately before and 10 seconds after initiation of
plaque rupture. Lipoxygenase (LO)-derived products, including LXA4 and
5S,12S-DiHETE, and a marker of cyclooxygenase activity, i.e., TXB2, were
quantitated after extraction and chromatography using deuterium- labeled
internal standards and electron capture negative ion chemical ionization
mass spectrometry. Peptidoleukotrienes (LTC4 and LTD4) were quantitated
after reverse-phase high-performance liquid chromatography coupled with
radioimmunoassay. Intracoronary blood taken before PTCA showed no
detectable levels of these eicosanoids (the minimum limits of detection
were within the picomole range). In contrast, each of these LO products was
detected after PTCA. Patients undergoing ASA treatment showed elevated
levels of each LO product examined compared with those not receiving ASA.
Eicosanoid levels were (mean +/- SEM): LTC4, 7.10 +/- 1.22 ng/ml (ASA)
versus 0.48 +/- 0.10 ng/ml; LTD4, 4.92 +/- 0.56 ng/ml (ASA) versus 1.17 +/-
0.48 ng/ml; LXA4, 24.98 +/- 4.11 ng/ml (ASA) versus 15.83 +/- 2.43 ng/ml;
5S,12S-DiHETE, 19.47 +/- 3.98 ng/ml (ASA) versus 11.98 +/- 1.83 ng/ml;
TXB2, complete blockage (ASA) versus 31.04 +/- 7.38 ng/ml (p less than 0.05
for LTC4 and LTD4). To distinguish between dilatation of whole blood versus
dilatation of whole blood and atheroma for contribution of eicosanoids, we
also monitored their formation in Gore-tex grafts. Upon balloon inflation,
TXB2 was generated, but LO products were not detected. In contrast,
injection of platelet- and leukocyte-directed agonists within the graft led
to both peptidoleukotriene and lipoxin formation. CONCLUSIONS. The results
indicate that PTCA triggers the intraluminal release of peptidoleukotrienes
and LXA4 and that ASA therapy enhances their appearance in intracoronary
blood. In addition, they provide direct evidence for LO products (LTC4,
LTD4, and LXA4) in a local milieu in vivo. Moreover, the presence of the
double dioxygenation product 5S,12S- DiHETE (a potential marker of 5- and
12-LO interactions) suggests that transcellular metabolic events can
contribute to eicosanoid formation in vivo.
ARTICLES
Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
This article has been cited by other articles:
 |
|
 |
|
  A. Di Gennaro, E. Kenne, M. Wan, O. Soehnlein, L. Lindbom, and J. Z. Haeggstrom Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin) FASEB J, June 1, 2009; 23(6): 1750 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Houard, V. Ollivier, L. Louedec, J.-B. Michel, and M. Back Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus FASEB J, May 1, 2009; 23(5): 1376 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hlawaty, M.-P. Jacob, L. Louedec, D. Letourneur, C. Brink, J.-B. Michel, L. Feldman, and M. Back Leukotriene Receptor Antagonism and the Prevention of Extracellular Matrix Degradation During Atherosclerosis and In-Stent Stenosis Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Merched, K. Ko, K. H. Gotlinger, C. N. Serhan, and L. Chan Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators FASEB J, October 1, 2008; 22(10): 3595 - 3606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Levy Myocardial 15-Epi-lipoxin A4 Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones Circulation, August 29, 2006; 114(9): 873 - 875. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, A.-S. Johansson, M. Sjostrom, M. Wan, O. Schroder, J. Palmblad, and J. Z. Haeggstrom Differential induction of BLT receptor expression on human endothelial cells by lipopolysacharide, cytokines, and leukotriene B4 PNAS, May 2, 2006; 103(18): 6913 - 6918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. McMahon and C. Godson Lipoxins: endogenous regulators of inflammation Am J Physiol Renal Physiol, February 1, 2004; 286(2): F189 - F201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Serhan, A. Jain, S. Marleau, C. Clish, A. Kantarci, B. Behbehani, S. P. Colgan, G. L. Stahl, A. Merched, N. A. Petasis, et al. Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators J. Immunol., December 15, 2003; 171(12): 6856 - 6865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gangemi, G. Luciotti, E. D'Urbano, A. Mallamace, D. Santoro, G. Bellinghieri, G. Davi, and M. Romano Physical exercise increases urinary excretion of lipoxin A4 and related compounds J Appl Physiol, June 1, 2003; 94(6): 2237 - 2240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Van Dyke and C.N. Serhan Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases Journal of Dental Research, February 1, 2003; 82(2): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, A. Ganci, A. Greco, M. R. Panara, M. Pasquale, D. Di Gregorio, E. Porreca, A. Mezzetti, F. Cuccurullo, and P. Patrignani Modulation of Aspirin-Insensitive Eicosanoid Biosynthesis by 6-Methylprednisolone in Unstable Angina Circulation, January 7, 2003; 107(1): 55 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kantarci and T. E. Van Dyke LIPOXINS IN CHRONIC INFLAMMATION Critical Reviews in Oral Biology & Medicine, January 1, 2003; 14(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Vaughn, R. J. Proske, and D. L. Haviland Identification, Cloning, and Functional Characterization of a Murine Lipoxin A4 Receptor Homologue Gene J. Immunol., September 15, 2002; 169(6): 3363 - 3369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Leonard, K. Hannan, M. J. Burne, D. W. P. Lappin, P. Doran, P. Coleman, C. Stenson, C. T. Taylor, F. Daniels, C. Godson, et al. 15-Epi-16-(Para-Fluorophenoxy)-Lipoxin A4-Methyl Ester, a Synthetic Analogue of 15-epi-Lipoxin A4, Is Protective in Experimental Ischemic Acute Renal Failure J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1657 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Maderna, C. Godson, G. Hannify, M. Murphy, and H. R. Brady Influence of lipoxin A4 and other lipoxygenase-derived eicosanoids on tissue factor expression Am J Physiol Cell Physiol, October 1, 2000; 279(4): C945 - C953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.L Mehta and D.Y Li Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain? Cardiovasc Res, August 1, 1999; 43(2): 291 - 299. [Full Text] [PDF]
|
|
|
|
|
|
S. Allen, M. Dashwood, K. Morrison, and M. Yacoub Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries Circulation, June 23, 1998; 97(24): 2406 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Datta, M. Romano, B. C. Jacobson, D. E. Golan, C. N. Serhan, and B. M. Ewenstein Peptido-Leukotrienes Are Potent Agonists of von Willebrand Factor Secretion and P-Selectin Surface Expression in Human Umbilical Vein Endothelial Cells Circulation, December 1, 1995; 92(11): 3304 - 3311. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Patrono Aspirin as an Antiplatelet Drug N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294. [Full Text]
|
|
|
|
 |
|
 H. Nagai, Y. Nakamura, S. Takata, and K.-i. Kobayashi Angina Pectoris Associated with ST Segment Elevation in the Absence of Epicardial Coronary Arterial Obstruction: Case Reports Angiology, May 1, 1994; 45(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Ware and D. D. Heistad Platelet-Endothelium Interactions N. Engl. J. Med., March 4, 1993; 328(9): 628 - 635. [Full Text]
|
|